High-intensity focused ultrasound (HIFU) is now showing promise as a non-invasive treatment for Parkinson’s disease symptoms—reducing tremors, stiffness, and pain without surgery. Published this week in The Lancet Neurology, Phase III trial results reveal a 40% improvement in motor function for eligible patients, with minimal adverse effects. But how does it work, who can access it, and what are the risks? Here’s what you need to know.
Parkinson’s disease affects over 10 million people globally, with 1 million new cases diagnosed annually [WHO, 2025]. Current treatments—like levodopa or deep brain stimulation (DBS)—manage symptoms but don’t halt neurodegeneration. Now, HIFU offers a targeted, reversible alternative by focusing ultrasound waves on the globus pallidus interna (a deep brain region linked to motor control), disrupting abnormal neural firing without damaging surrounding tissue. This is the first time a non-pharmacological, non-surgical therapy has demonstrated such efficacy in large-scale trials.
In Plain English: The Clinical Takeaway
- What it does: HIFU “silences” overactive brain circuits causing tremors and stiffness—like a volume knob turned down on a faulty amplifier.
- How it’s done: Patients undergo a 3-hour outpatient procedure with MRI-guided precision; no anesthesia or incisions are needed.
- Who benefits: Early-stage Parkinson’s patients (Hoehn & Yahr stages 2–3) with unilateral symptoms see the most improvement.
How HIFU Disrupts Parkinson’s Pathophysiology: The Science Behind the Sound
Parkinson’s is driven by the loss of dopaminergic neurons in the substantia nigra, leading to excessive activity in the basal ganglia circuit. HIFU’s mechanism of action involves creating thermal lesions (controlled heating) in the globus pallidus interna, which modulates the circuit’s hyperactivity. Unlike DBS (which requires implanted electrodes), HIFU is reversible—if side effects emerge, the effect can be “undone” with repeat treatments.
Key trial data from the SONOPARK study (N=300, multicenter, double-blind placebo-controlled) showed:
- 40% reduction in tremor severity at 6 months (vs. 10% in sham-treated controls).
- 30% improvement in stiffness (measured via Unified Parkinson’s Disease Rating Scale).
- No cognitive decline observed in post-treatment neuroimaging.
The thermal dose (energy delivered) was calibrated to 57°C for 16 seconds, a threshold proven safe in prior neurostimulation trials [JAMA Neurology, 2024]. However, the effect is temporary—median duration is 18–24 months, necessitating repeat sessions.
Global Access: Regulatory and Healthcare System Realities
The U.S. FDA granted Breakthrough Device Designation in February 2026, accelerating review for Exablate Neuro (Insightec’s HIFU system). Approval is expected by late 2027, with commercial launch priced at $50,000–$75,000 per treatment—a barrier for many. In contrast, the European Medicines Agency (EMA) is conducting a conditional approval pathway, prioritizing access in the UK’s NHS and German healthcare systems, where Parkinson’s prevalence is 200/100,000 [ECDC, 2025].
“HIFU’s advantage is its scalability. Unlike DBS, which requires neurosurgery, this could be deployed in regional hospitals with minimal training. The challenge is ensuring equitable access—we’re seeing a digital divide where wealthier nations adopt it first.”
—Dr. Lars Forsgren, Chief Neurologist, Karolinska Institute (Sweden)
In low-resource settings (e.g., Sub-Saharan Africa, where Parkinson’s is underdiagnosed), HIFU’s high cost may limit uptake. The World Health Organization (WHO) has flagged this as a priority for global health innovation funds, with pilot programs planned in India and Brazil.
Funding and Conflicts: Who’s Driving the Research?
The SONOPARK trial was funded by a $40 million public-private partnership between:
- Insightec (HIFU device manufacturer, Israel/US)
- Michael J. Fox Foundation (patient advocacy)
- NIH/NINDS (National Institute of Neurological Disorders and Stroke)
While industry funding is common in device trials, the independent data safety monitoring board (chaired by The Lancet’s neurology editor) ensured transparency. A 2025 meta-analysis in JAMA found no bias in outcomes when comparing industry-funded vs. NIH-funded neurostimulation studies.
Debunking the Myths: What HIFU *Doesn’t* Do
Myth 1: “HIFU cures Parkinson’s.” Reality: It targets symptoms, not the underlying alpha-synuclein pathology. Trials showed no slowing of disease progression in biomarkers like dopamine transporter (DAT) scans [Neurology, 2026].
Myth 2: “It’s risk-free.” Reality: Rare but serious side effects include transient dysphagia (swallowing difficulty, 1.2% of patients) and mild hemiparesis (weakness on one side, 0.5%). These resolve within 3 months but warrant speech therapy pre- and post-procedure.
Myth 3: “Only old people benefit.” Reality: The trial included patients aged 35–85, with 30% under 60. Younger patients saw faster motor recovery, likely due to preserved neural plasticity.
| Metric | HIFU Group (N=200) | Sham Group (N=100) | P-Value |
|---|---|---|---|
| Tremor Reduction (%) | 40% | 10% | <0.001 |
| Stiffness Improvement (UPDRS Part III) | 30% | 5% | <0.001 |
| Pain Relief (VAS Score) | 45% | 15% | <0.001 |
| Duration of Effect (Months) | 18–24 | N/A | – |
Contraindications & When to Consult a Doctor
HIFU is not suitable for patients with:
- Severe cognitive impairment (MMSE <24), as thermal lesions could exacerbate confusion.
- Active brain metastases or untreated epilepsy (risk of seizure provocation).
- Uncontrolled hypertension (BP >160/100 mmHg), due to vasomotor instability during heating.
- Pregnancy (safety in in utero exposure not established).
Seek emergency care if:
- Sudden slurred speech or difficulty swallowing post-treatment.
- Worsening headache with nausea/vomiting (possible subdural hematoma, though rare).
- New-onset seizures (incidence: <0.1% in trials).
The Road Ahead: What’s Next for HIFU in Parkinson’s?
While HIFU is a game-changer for symptomatic relief, the field is now focusing on:
- Combination therapy: Trials are underway pairing HIFU with AAV2-GAD gene therapy (a neuroprotective approach) [ClinicalTrials.gov: NCT05234567].
- Early intervention: The PARK-HIFU study (UK) is enrolling pre-motor Parkinson’s patients to test if HIFU can delay symptom onset.
- Cost reduction: Insightec is developing a $20,000 portable HIFU unit for clinics in India and Latin America.
“This is the first time we’ve had a non-destructive, non-invasive tool to modulate deep brain circuits. The next frontier is using HIFU to stimulate rather than lesion—like a ‘neural pacemaker’ without electrodes.”
—Dr. Helen Bronte-Stewart, Stanford Neurology, Lead Investigator, SONOPARK-2
For now, patients should consult a movement disorder specialist to assess eligibility. While HIFU isn’t a cure, it offers a less invasive alternative to DBS—one that could redefine Parkinson’s management in the next decade.
References
- The Lancet Neurology (2026). “High-Intensity Focused Ultrasound for Parkinson’s Disease: A Phase III Randomized Trial.”
- JAMA Neurology (2024). “Safety of Thermal Lesioning in the Basal Ganglia: A Systematic Review.”
- World Health Organization (2025). “Parkinson’s Disease: Global Burden and Treatment Gaps.”
- European Centre for Disease Prevention and Control (2025). “Neurodegenerative Diseases in Europe.”
- ClinicalTrials.gov (2023). “PARK-HIFU: Early-Stage Parkinson’s Intervention Study.”
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before pursuing new treatments.
